Vistagen therapeutics stock.
Nov 30, 2023 · 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.
According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.About VTGN. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ...
The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023. 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents ...
Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen common stock, accompanying warrants to purchase up to 9,294,022 shares of Vistagen common stock (or pre-funded warrants in lieu thereof) at an exercise ...
Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval. Nov 9, 2023 · MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript. Get the latest Vistagen Therapeutics, Inc. (VTGN) stock news and headlines to help you in your trading and investing ...
Nov 29, 2023 · See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged ...
The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and...Currently, the analyst consensus on VistaGen Therapeutics is a Moderate Buy with an average price target of $30.00. See today’s best-performing stocks on TipRanks >> VTGN market cap is currently ...View the latest VistaGen Therapeutics Inc. (VTGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Mentioned in this article. Vistagen Therapeutics Inc ( VTGN) is up 0.39% today. VTGN has an Overall Score of 76. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $5.12 and is up $0.02 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most …VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.
See Vistagen Therapeutics, Inc. (VTGN) history of stock splits. Includes date and ratio.VistaGen Therapeutics Stock Prediction 2030. In 2030, the VistaGen Therapeutics stock will reach $ 228.74 if it maintains its current 10-year average growth rate. If this VistaGen Therapeutics stock prediction for 2030 materializes, VTGN stock willgrow 6,271.71% from its current price. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ...Vistagen common stock will begin trading. SOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, …Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and market outlook for the first quarter of 2024.Find the latest news headlines from VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.
Nov 24, 2023 · 33. Shawn Singh. https://www.vistagen.com. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates ...
7.32%. $1.48B. VTGN | Complete VistaGen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Benzinga - by Vandana Singh, Benzinga Editor. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage …The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ...This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.Vistagen Therapeutics ( NASDAQ: VTGN) added ~17% on Tuesday after Stifel initiated its coverage with a Buy recommendation citing a potential blockbuster opportunity for its anxiety disorder drug ...Find the latest Earnings Report Date for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.
In a week that has seen Vistagen Therapeutics' stock triple in value, investors and company watchers have been intensely focused on the company. The fervor was in response to the positive Phase 3 ...
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety ...
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders.Apr 20, 2023 · SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ... SOUTH SAN FRANCISCO, Calif., October 02, 2023--Vistagen Therapeutics, Inc. ("Vistagen") (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape ...Benzinga - by Vandana Singh, Benzinga Editor. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other mental health conditions.. The lead product …33. Shawn Singh. https://www.vistagen.com. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates ...At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small ...If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements. Investors. Mark McPartland. Senior Vice President, Investor Relations (650) 577-3606. [email protected]. Media. Nate Hitchings. …Dec 1, 2023 · Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; Section 16 Filings; Corporate Governance Executive Team; Board Committees; Documents & Charters Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and market outlook for the first quarter of 2024.
Sep 21, 2023 · Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ... Dec 6, 2022 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... According to data from Benzinga Pro, VistaGen Therapeutics shares were up 17.6%, trading at $0.16 at the time of publication. The stock has a 52-week high of $1.79 and a 52-week low of $0.08.Vistagen Therapeutics is a biopharmaceutical company that develops products for anxiety, depression, and CNS disorders. The stock has a consensus rating …Instagram:https://instagram. lincoln bicentennial penniesstock upgrades downgradessilicon valley incubatorhalf dollar 1964 coin value Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results.The pharmaceutical producer has been struggling all year, dipping into penny ... bullbear tradersnestle stocks At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small ... amdy etf Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. (“Fuji”) (TSE: 4554), a pharmaceutical company specializing in development, manufacture and …Get the latest Viking Therapeutics Inc (VKTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.VistaGen Therapeutics (VTGN) stock price prediction is 4.1154543085612 USD. The VistaGen Therapeutics stock forecast is 4.1154543085612 USD for 2024 ...